



AGENDA Forum and Webinar

Thursday, September 1, 2022
Fairmont Century Plaza, Los Angeles
9:30 am -12:30 pm PST

I. Welcome to CAN's Inaugural Forum

Nancy Davis | Founder and President of CAN

II. Moderator and Introduction of Panel

Kurt Rasmussen, Ph.D., CSO Delix Therapeutics | CAN Scientific Advisory Board

- **Topic 1:** Evaluation of a new FDA-approved non-narcotic medication, suvorexant (Belsomra), for the treatment of insomnia during opioid withdrawal and directly reduced the severity of withdrawal and craving, with no identified risk for misuse.
Presenter: Kelly E. Dunn, Ph.D., Johns Hopkins School of Medicine | CAN Team | CAN Grant Recipient
- **Topic 2:** Breaking the cycle of opioid use disorder with Ibogaine.
Presenter: Deborah C. Mash, Ph.D., University of Miami School of Medicine | CAN Scientific Advisory Board
- **Topic 3:** Psychedelics in SUD.
Presenter: Matthew W. Johnson, Ph.D., Johns Hopkins University School of Medicine | Guest Speaker
- **Topic 4:** Development of Nasal Nalmefene for Opioid Overdose.
Presenter: Roger Crystal, MD, President, Chief Executive Officer, Opiant Pharmaceuticals, Inc. | Guest Speaker
- **Topic 5:** Current research - novel "chemical sensing" mechanism that detects the presence of opioids and other addictive drugs in the body before they reach the brain, which is involved in controlling subsequent addiction-related actions of the drugs.
Presenter: Paul J. Kenny, Ph.D., Mount Sinai | CAN Team | CAN Grant Recipient
- **Topic 6:** Development of a single use medication for the treatment of substance use disorder.
Presenter: Courtney Miller, Ph.D., UF Scripps Biomedical Research | CAN Team | CAN Grant Recipient
- **Topic 7:** The risks of taking an Opioid.
Presenter: Chris Evans Ph.D., Stefan Hatos Professor, UCLA | CAN Team
- **Topic 8:** Kappa opioid receptors as a target for treating opioid use disorder.
Presenter: Catherine M. Cahill, Ph.D., UCLA | CAN Grant Recipient
- **Topic 9:** The connection between mental health and substance use disorder.
Presenter: Adam Kaplin, M.D, Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals | CAN Team

III. Loss and Living with Substance Use Disorder

Jodi Barber and Jason Wahler | Guest Speakers

IV. Lightning Round: Answers to submitted questions

V. Conclusion and thank you by Nancy Davis